Can Ozempic & Wegovy Help Quit Smoking?

Recent research suggests that semaglutide, the active ingredient in medications like Ozempic and Wegovy, could potentially play a role in treating addiction. A study found that individuals who were prescribed semaglutide for type 2 diabetes were less likely to seek medical care for tobacco use compared to those taking other diabetes medications. This finding adds to the growing interest in exploring how semaglutide might influence behaviors beyond its primary use for weight loss and diabetes management.

In this article, you will learn about the potential effects of Ozempic and Wegovy on smoking cessation, the science behind how these drugs might reduce nicotine cravings, and what experts say about their effectiveness in helping people quit smoking.

What are Ozempic and Wegovy?

Ozempic and Wegovy are two medications that contain the active ingredient semaglutide, a GLP-1 receptor agonist. Originally developed to manage type 2 diabetes, these drugs have gained significant attention for their effectiveness in promoting weight loss. Ozempic is primarily prescribed for diabetes management, while Wegovy is approved for weight loss in individuals with obesity or overweight conditions. Both drugs work by mimicking the effects of the GLP-1 hormone, which increases insulin secretion, slows gastric emptying, and reduces appetite, leading to better blood sugar control and weight reduction.

How Does Semaglutide Affect Nicotine Cravings?

Semaglutide’s potential to reduce nicotine cravings is rooted in its impact on the brain’s reward system. The brain’s reward center, which is activated by pleasurable activities like eating, socializing, or using nicotine, releases dopamine—a neurotransmitter associated with feelings of pleasure and reinforcement. This dopamine surge encourages repeated behavior, contributing to addiction.

GLP-1 drugs, including semaglutide, may reduce dopamine release in response to certain stimuli, thereby decreasing cravings. A study on rodents indicated that semaglutide might reduce nicotine addiction by modulating the brain’s reward and aversive systems. This modulation potentially lessens the dopamine surge associated with nicotine use, diminishing the reinforcement of the behavior.

Another factor contributing to semaglutide’s impact on nicotine cravings is its effect on body weight. Semaglutide is known for its weight loss benefits. The fear of weight gain is a common concern among individuals attempting to quit smoking, often leading to smoking relapse. By helping users lose weight or maintain a healthier weight, semaglutide might indirectly reduce the risk of tobacco use disorder.

According to the authors of a recent study, “The mechanisms underlying the observed lower-risk associations of semaglutide with [tobacco use disorder]-related measures are unclear. But preclinical studies suggest that they likely reflect the involvement of GLP-1 receptors in modulating the brain’s reward and aversive systems.” They further noted, “The reduction in body weight associated with [semaglutide] might have also contributed to the reduced risk for [tobacco use disorder]-related measures because fear of weight gain on smoking cessation contributes to smoking and relapse.”

How Do Ozempic and Wegovy Help Reduce Smoking Cravings?

Ozempic and Wegovy may help reduce smoking cravings by influencing the brain’s reward centers. When people engage in pleasurable activities, such as smoking, dopamine levels surge, reinforcing the behavior. However, semaglutide may reduce the release of dopamine in response to nicotine, making smoking less rewarding and potentially decreasing cravings.

Recent research supports this idea. A study from Case Western Reserve University School of Medicine found that semaglutide is linked to a lower risk for tobacco use disorder in smokers with type 2 diabetes. Professor Wong Shu, who contributed to the study, stated during her interview in the News 5 Cleveland, “We found the people taking semaglutide have a significantly lower need to visit a doctor for the nicotine use disorder diagnosis. Also, they have a significantly lower risk for the need for smoking cessation”

Recent research published in the Annals of Internal Medicine found that semaglutide is associated with a lower likelihood of needing smoking cessation interventions, such as medications or counseling. The study examined the health data of nearly 223,000 individuals, including around 6,000 who took semaglutide.

Researchers found that those taking semaglutide had a significantly lower risk of requiring medical encounters for tobacco use disorder compared to those taking other diabetes medications like insulin or metformin. The study’s findings suggest that people on semaglutide might be more successful at quitting smoking, with noticeable effects seen within just 30 days of starting the medication. This reduction in nicotine cravings may be due to semaglutide’s impact on the brain’s reward centers, which diminishes the dopamine surge linked to smoking.

What Do Experts Say About Using Ozempic and Wegovy for Smoking Cessation?

Medical professionals and researchers are cautiously optimistic about the potential of semaglutide-based drugs like Ozempic and Wegovy in smoking cessation. The recent study has sparked interest in the broader applications of these drugs beyond diabetes and weight loss. Researchers from the US National Institute on Drug Abuse, who contributed to the study, emphasized that “Semaglutide was associated with a significantly lower risk for medical encounters for tobacco use disorder diagnosis compared with other antidiabetes medications.”

The study’s authors also noted, “Semaglutide was associated with reduced smoking cessation medication prescriptions and counseling,” indicating that the drug’s impact on the brain’s reward centers might be a key factor in its effectiveness.

However, experts caution that while these findings are promising, more research is needed. The current study did not specifically focus on smoking cessation, and there were limitations, such as potential documentation bias and missing data on participants’ current smoking behavior. Therefore, scientists call for clinical trials specifically designed to evaluate semaglutide’s potential as a smoking cessation aid.

What Are the Risks of Using Ozempic & Wegovy to Quit Smoking?

While Ozempic and Wegovy show potential in helping reduce nicotine cravings, there are several risks and limitations to consider. These drugs were originally developed to treat type 2 diabetes and obesity, not as smoking cessation aids. As such, their use for quitting smoking is off-label, meaning it is not officially approved for this purpose.

One of the main concerns is the lack of extensive clinical trials specifically focused on smoking cessation. The current studies, including the one published in the Annals of Internal Medicine, suggest that semaglutide may reduce the need for smoking cessation interventions. However, these findings are preliminary, and the study itself has limitations, such as potential documentation bias and missing data on participants’ smoking behaviors. As noted in the study, “there may have been documentation bias and missing data on current smoking behavior of the participants,” which could affect the reliability of the results.

Additionally, semaglutide is associated with several side effects that could deter some individuals from using these drugs for smoking cessation. These side effects include:

• Abdominal pain
• Constipation
• Diarrhea
• Nausea and vomiting

These side effects could be particularly challenging for individuals trying to quit smoking, as they may already be experiencing withdrawal symptoms. There’s also the risk of hypoglycemia, especially in those who do not have diabetes but are considering using these drugs for smoking cessation.

Experts emphasize that while the reduction in nicotine cravings is promising, more clinical trials are necessary to confirm these effects and to understand the long-term risks of using semaglutide for smoking cessation.

Is Ozempic or Wegovy Right for You If You Want to Quit Smoking?

Deciding whether Ozempic or Wegovy is suitable for smoking cessation should be based on individual health needs and a thorough discussion with a healthcare professional. Here are some considerations:

Who Might Consider These Drugs?

• Individuals with Type 2 Diabetes or Obesity: Those already prescribed semaglutide for diabetes or weight management may find an added benefit in reduced nicotine cravings.

• People Struggling with Traditional Methods: For individuals who have not succeeded with conventional smoking cessation treatments, semaglutide could be an alternative option.

• Those at Risk of Weight Gain: Since semaglutide helps with weight management, it may be beneficial for smokers concerned about weight gain upon quitting.

Before starting semaglutide for smoking cessation, it is crucial to consult with a healthcare provider to assess:

• Medical History: A thorough review of your health conditions and current medications to avoid any adverse interactions.

• Potential Side Effects: Understanding the risks and managing side effects appropriately.

• Customized Plan: Develop a comprehensive cessation plan that may include semaglutide as part of a broader strategy.

Other Smoking Cessation Treatments Available

Several proven treatments are already available to help people quit smoking, including:

• Counseling and Behavioral Therapy: Support from healthcare professionals to develop strategies and coping mechanisms.

• Nicotine Replacement Therapy (NRT): Options like nicotine patches, gum, and lozenges.

• Prescription Medications: Varenicline and bupropion are commonly prescribed to reduce cravings and withdrawal symptoms.

Despite these options, many individuals still find it challenging to quit smoking. Johannes noted, “Even with medications and nicotine replacement therapy, it can be very difficult for some people to stop smoking, in part because they may not be ready to stop or may not want to stop right then. So we could use some better treatments.”

Conclusion

While Ozempic and Wegovy, both containing semaglutide, show promising potential in reducing smoking cravings and supporting smoking cessation efforts, their use for this purpose is considered off-label and not officially approved. The ability of semaglutide to influence the brain’s reward system and its benefits in weight management may offer added advantages for individuals looking to quit smoking.

However, the side effects and the need for more targeted research are important considerations. For those already using these medications for diabetes or weight loss, the potential to reduce smoking cravings could be an added benefit. Further studies will be necessary to fully understand and confirm the effectiveness of semaglutide in smoking cessation.

Frequently Asked Questions